Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III trial of recombinant COVID-19 vaccine (Sf9 cells) in adults
PACTR202103845381761Phase 3Not yet recruiting
- Sponsor
- WestVac Biopharma
- Start
- Apr 2021
- Modality
- Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Recombinant COVID-19 vaccine (Sf9 cells) with Placebo (2 arms). Planned start Apr 2021; status: not yet recruiting.
02
Drugs
recombinant COVID-19 (XBB) trimer protein vaccine
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on PACTR202103845381761.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202103845381761.